Literature DB >> 2828074

Reinduction chemotherapy in small cell lung cancer.

G Giaccone1, P Ferrati, M Donadio, F Testore, A Calciati.   

Abstract

Thirteen patients with small cell lung cancer responsive to chemotherapy were retreated with the same regimen at relapse, after a median off-therapy time of 30 weeks. Fifty per cent responded to reinduction; two out of six patients who had complete response to first chemotherapy obtained complete response again at reinduction. Median survival time from start of any therapy was 94 weeks. When induction chemotherapy has been effective and of short duration, the same chemotherapy can be attempted again with success at relapse and it may affect survival of relapsing small cell lung cancer patients.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2828074     DOI： 10.1016/0277-5379(87)90452-4

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


  30 in total

1.  Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.

Authors:  P Collard; P Weynants; C Francis; D O Rodenstein
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

Review 2.  SEOM clinical guidelines for the treatment of small-cell lung cancer 2013.

Authors:  M Dómine Gómez; T Morán Bueno; A Artal Cortés; J Remon Masip; P Lianes Barragán
Journal:  Clin Transl Oncol       Date:  2013-09-05       Impact factor: 3.405

Review 3.  Chemotherapy advances in small-cell lung cancer.

Authors:  Bryan A Chan; Jermaine I G Coward
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 4.  Small cell lung cancer: therapies and targets.

Authors:  Rathi N Pillai; Taofeek K Owonikoko
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

5.  A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer.

Authors:  E F Smit; H H Berendsen; E G de Vries; N H Mulder; P E Postmus
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer.

Authors:  Yingming Zhu; Ke Tang; Fen Zhao; Yuanwei Zang; Xiaodong Wang; Zhenxiang Li; Xindong Sun; Jinming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-29       Impact factor: 4.553

7.  Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation.

Authors:  Masakuni Sakaguchi; Toshiya Maebayashi; Takuya Aizawa; Naoya Ishibashi; Tsutomu Saito
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

8.  Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.

Authors:  Yoshiko Naito; Kazuhiko Yamada; Yohei Imamura; Hidenobu Ishii; Norikazu Matsuo; Takaaki Tokito; Takashi Kinoshita; Koichi Azuma; Tomoaki Hoshino
Journal:  Med Oncol       Date:  2018-04-02       Impact factor: 3.064

Review 9.  Relapsed small cell lung cancer: treatment options and latest developments.

Authors:  Nobuhiro Asai; Yoshihiro Ohkuni; Norihiro Kaneko; Etsuro Yamaguchi; Akihito Kubo
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

10.  E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.

Authors:  Taofeek K Owonikoko; Joseph Aisner; Xin Victoria Wang; Suzanne E Dahlberg; Eric H Rubin; Suresh S Ramalingam; Murugesan Gounder; Paul Gregory Rausch; Rita S Axelrod; Joan H Schiller
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-28       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.